The U.S. Supreme Court unanimously ruled in favor of Hikma Pharmaceuticals in a key “skinny label” case involving Amarin’s Vascepa, affirming that Hikma’s generic did not infringe Amarin’s patents as marketed for approved uses. The 9–0 opinion overturned a lower-court decision and strengthens the viability of skinny-label strategies for generic entry. The decision centers on patent scope tied to Vascepa indications: while severe hypertriglyceridemia patents were invalidated earlier, Amarin retained protection for less-elevated triglyceride use. Hikma argued its marketing and prescribing did not meet the standards for infringement on the protected indication. For the biotech and pharma industry, the ruling is a concrete legal signal for how patent infringement theories tied to labeling and marketing will be evaluated, with direct implications for generic competition planning and future litigation risk models.